Bone health in cancer: ESMO Clinical Practice Guidelines

被引：292
作者：
Coleman, R. [1 ]
Hadji, P. [2 ,3 ]
Body, J-J [4 ]
Santini, D. [5 ]
Chow, E. [6 ]
Terpos, E. [7 ]
Oudard, S. [8 ]
Bruland, O. [9 ,10 ]
Flamen, P. [11 ]
Kurth, A. [12 ,13 ]
Van Poznak, C. [14 ]
Aapro, M. [15 ]
Jordan, K. [16 ]
机构：
[1] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[2] Frankfurt Ctr Bone Hlth, Frankfurt, Germany
[3] Philipps Univ Marburg, Marburg, Germany
[4] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium
[5] Univ Campus Biomed, Med Oncol Dept, Rome, Italy
[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[7] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[8] Paris Descartes Univ, Georges Pompidou Hosp, Dept Med Oncol, Paris, France
[9] Univ Oslo, Inst Clin Med, Oslo, Norway
[10] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway
[11] Univ Libre Bruxelles, Inst Jules Bordet, Dept Nucl Med, Brussels, Belgium
[12] Community Clin Middle Rhine, Dept Orthopaed & Trauma Surg, Campus Kemperhof, Koblenz, Germany
[13] Univ Med Mainz, Major Teaching Hosp, Mainz, Germany
[14] Univ Michigan, Ann Arbor, MI 48109 USA
[15] Genolier Canc Ctr, Genolier, Switzerland
[16] Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷 / 12期
关键词：
bone metastases; cancer treatment-induced bone loss; bone-targeted agents; Clinical Practice Guidelines; diagnosis; treatment; follow-up; EARLY BREAST-CANCER; ZOLEDRONIC ACID; MULTIPLE-MYELOMA; DOUBLE-BLIND; SOLID TUMORS; OPEN-LABEL; DENOSUMAB; METASTASES; PHASE-3; SURVIVAL;
D O I：
10.1016/j.annonc.2020.07.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1650 / 1663
页数：14
相关论文
共 44 条
  • [1] Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
    Barrett-Lee, Peter
    Casbard, Angela
    Abraham, Jacinta
    Hood, Kerenza
    Coleman, Robert
    Simmonds, Peter
    Timmins, Hayley
    Wheatley, Duncan
    Grieve, Robert
    Griffithst, Gareth
    Murray, Nick
    [J]. LANCET ONCOLOGY, 2014, 15 (01) : 114 - 122
  • [2] Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management
    Black, Dennis M.
    Abrahamsen, Bo
    Bouxsein, Mary L.
    Einhorn, Thomas
    Napoli, Nicola
    [J]. ENDOCRINE REVIEWS, 2019, 40 (02) : 333 - 368
  • [3] Bone health in the elderly cancer patient: A SIOG position paper
    Body, J. J.
    Terpos, E.
    Tombal, B.
    Hadji, P.
    Arif, A.
    Young, A.
    Aapro, M.
    Coleman, R.
    [J]. CANCER TREATMENT REVIEWS, 2016, 51 : 46 - 53
  • [4] Skeletal Metastasis Evaluation Value and Impact of PET/Computed Tomography on Diagnosis, Management and Prognosis
    Broski, Stephen M.
    Young, Jason R.
    Kendi, Ayse T.
    Subramaniam, Rathan M.
    [J]. PET CLINICS, 2019, 14 (01) : 103 - +
  • [5] Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
    Coleman, R.
    Powles, T.
    Paterson, A.
    Gnant, M.
    Anderson, S.
    Diel, I.
    Gralow, J.
    von Minckwitz, G.
    Moebus, V.
    Bergh, J.
    Pritchard, K. I.
    Bliss, J.
    Cameron, D.
    Evans, V.
    Pan, H.
    Peto, R.
    Bradley, R.
    Gray, R.
    Bartsch, R.
    Dubsky, P.
    Fesl, C.
    Fohler, H.
    Greil, R.
    Jakesz, R.
    Lang, A.
    Luschin-Ebengreuth, G.
    Marth, C.
    Mlineritsch, B.
    Samonigg, H.
    Singer, C. F.
    Steger, G. G.
    Stoeger, H.
    Olivotto, I.
    Ragaz, J.
    Christiansen, P.
    Ejlertsen, B.
    Ewertz, M.
    Jensen, M-B
    Moller, S.
    Mouridsen, H. T.
    Eiermann, W.
    Hilfrich, J.
    Jonat, W.
    Kaufmann, M.
    Kreienberg, R.
    Schumacher, M.
    Blohmer, J. U.
    Costa, S. D.
    Eidtmann, H.
    Gerber, B.
    [J]. LANCET, 2015, 386 (10001) : 1353 - 1361
  • [6] Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
    Coleman, Robert
    Finkelstein, Dianne M.
    Barrios, Carlos
    Martin, Miguel
    Iwata, Hiroji
    Hegg, Roberto
    Glaspy, John
    Montano Perianez, Alvaro
    Tonkin, Katia
    Deleu, Ines
    Sohn, Joohyuk
    Crown, John
    Delaloge, Suzette
    Dai, Tian
    Zhou, Ying
    Jandial, Danielle
    Chan, Arlene
    [J]. LANCET ONCOLOGY, 2020, 21 (01) : 60 - 72
  • [7] Coleman R, 2019, BREAST, V48, pS92, DOI 10.1016/S0960-9776(19)31133-6
  • [8] Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial
    Coleman, Robert
    Hall, Andrew
    Albanell, Joan
    Hanby, Andrew
    Bell, Richard
    Cameron, David
    Dodwell, David
    Marshall, Helen
    Jean-Mairet, Joel
    Tercero, Juan-Carlos
    Rojo, Federico
    Gregory, Walter
    Gomis, Roger R.
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1543 - 1552
  • [9] Consensus on the utility of bone markers in the malignant bone disease setting
    Coleman, Robert
    Costa, Luis
    Saad, Fred
    Cook, Richard
    Hadji, Peyman
    Terpos, Evangelos
    Garnero, Patrick
    Brown, Janet
    Body, Jean-Jacques
    Smith, Matthew
    Lee, Ker-Ai
    Major, Pierre
    Dimopoulos, Meletios
    Lipton, Allan
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 80 (03) : 411 - 432
  • [10] Clinical features of metastatic bone disease and risk of skeletal morbidity
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6243S - 6249S
12345